Por favor, use este identificador para citar o enlazar este documento: https://hdl.handle.net/2445/177724
Título: Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry
Autor: Ayala Gutiérrez, María del Mar
Rubio-Rivas, Manuel
Romero Gómez, Carlos
Montero Saez, Abelardo
Pérez de Pedro, Iván
Homs Martí, Narcís
Ayuso García, Blanca
Cuenca Carvajal, Carmen
Arnalich Fernández, Francisco
Beato Pérez, José Luis
Vargas Núñez, Juan Antonio
Letona Giménez, Laura
Suárez Fernández, Carmen
Méndez Bailón, Manuel
Tuñón de Almeida, Carlota
González Moraleja, Julio
Guzmán García-Monge, Mayte de
Helguera Amezua, Cristina
Fidalgo Montero, María
Giner Galvañ, Vicente
Gil Sánchez, Ricardo
Collado Sáenz, Jorge
Boixeda, Ramon
Ramos-Rincón, José Manuel
Gómez Huelgas, Ricardo
SEMI-COVID-19 Network
Materia: Malalties autoimmunitàries
COVID-19
SARS-CoV-2
Autoimmune diseases
COVID-19
SARS-CoV-2
Fecha de publicación: 23-abr-2021
Publicado por: MDPI
Resumen: (1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.
Nota: Reproducció del document publicat a: https://doi.org/10.3390/jcm10091844
Es parte de: Journal of Clinical Medicine, 2021, vol. 10, num. 9
URI: https://hdl.handle.net/2445/177724
Recurso relacionado: https://doi.org/10.3390/jcm10091844
Aparece en las colecciones:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Archivos de este documento:
Archivo Descripción DimensionesFormato 
jcm-10-01844-v2.pdf341.28 kBAdobe PDFMostrar/Abrir


Este documento está sujeto a una Licencia Creative Commons Creative Commons